24/7 Patient Assistance: 760-405-8205

Omid Hamid, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Lung Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

  • Bio & Insurance Information

    Dr. Omid Hamid is a medical oncology specialist in Los Angeles, California and he works at several hospitals in the area, including St. John's Health Center and Cedars-Sinai Medical Center. He got his diploma from Keck School of Medicine of USC and did his residency in internal medicine at the University of Southern California - LAC+USC Medical Center, where he also did two fellowships in hematology and medical oncology. The doctor is certified in medical oncology and has an experience of more than 20 years.

  • Education & Training


    Keck School of Medicine of USC

    Medical School


    University of Southern California - LAC+USC Medical Center



    University of Southern California - LAC+USC Medical Center


  • Board Certifications

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Cedars-Sinai Medical Center

    Languages: English/Spanish

    (310) 423-3277

    8700 Beverly Blvd

    Los Angeles, California 90048

    Read More

    Providence Saint John's Health Center

    Languages: English/Spanish

    (310) 829-5511

    2121 Santa Monica Boulevard

    Santa Monica, California 90404

    Read More

    Ronald Reagan UCLA Medical Center

    Languages: English/Spanish

    (310) 825-9111

    757 Westwood Plaza

    Los Angeles, California 90095

    Read More
  • Publications & Memberships

    Dr. Omid Hamid has contributed to 3 publications.

    Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

    Hodi, F. S.,Hwu, W. J.,Kefford, R.,Weber, J. S.,Daud, A.,Hamid, O.,Patnaik, A.,Ribas, A.,Robert, C.,Gangadhar, T. C.,Joshua, A. M.,Hersey, P.,Dronca, R.,Joseph, R.,Hil...; J. Clin. Oncol.. 2016 Mar 09.

    See more >>

    Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

    Corcoran, R. B.,Atreya, C. E.,Falchook, G. S.,Kwak, E. L.,Ryan, D. P.,Bendell, J. C.,Hamid, O.,Messersmith, W. A.,Daud, A.,Kurzrock, R.,Pierobon, M.,Sun, P.,Cunningham...; J. Clin. Oncol.. 2015 Sep 24.

    See more >>

    Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma.

    Flaherty, D. C.,Hoffner, B. W.,Lau, B. J.,Hamid, O.,Faries, M. B.; J Surg Oncol. 2015 Oct 28.

    See more >>


    American Society of Clinical Oncology